Physician profile
Lourdes Lago
NPI 1720316037
$2,402.78
in general payments reported to CMS, 2019-2025
26 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $198 · 2021: $78.73 · 2022: $161 · 2023: $109 · 2024: $412 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,605 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,604.98 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $427.12 | 2023-2025 | |
| Eisai INC. | $336.59 | 2024-2025 | |
| Allergan, INC. | $245.32 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $240.71 | 2022-2025 | Xeomin, Inbrija |
| Teva Pharmaceuticals USA, INC. | $166.63 | 2023-2025 | Austedo Xr, Austedo Xr |
| Acadia Pharmaceuticals INC | $145.40 | 2020-2025 | Nuplazid |
| Lundbeck LLC | $82.31 | 2025 | Rexulti |
| Banner Life Sciences, LLC | $81.59 | 2024 | |
| Mdd US Operations, LLC | $81.58 | 2019 | |
| Cycle Pharmaceuticals INC | $64.72 | 2025 | Bafiertam |
| Neurocrine Biosciences, INC. | $56.26 | 2020-2024 | Ingrezza |
| Lilly USA, LLC | $55.03 | 2024-2025 | Kisunla |
| Argenx US, INC. | $48.93 | 2023 | Vyvgart, Vyvgart Hytrulo |
| C2n Diagnostics, LLC | $46.56 | 2025 | Precivityad2 |
| Adamas Pharmaceuticals, INC. | $44.88 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $44.12 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Abbott Laboratories | $40.90 | 2024-2025 | Infinity |
| Tanabe Pharma America, INC. | $33.17 | 2025 | Radicava |
| Sk Life Science, INC. | $32.72 | 2025 | |
| Ge Healthcare | $24.87 | 2020 | |
| Amgen INC. | $24.17 | 2025 | Uplizna |
| Emd Serono, INC. | $18.87 | 2023 | Mavenclad |
| Biogen, INC. | $16.31 | 2021 | |
| Alexion Pharmaceuticals, INC. | $16.14 | 2025 | Ultomiris |
| Kyowa Kirin, INC. | $15.43 | 2024 | Nourianz |
| Corium, LLC | $12.45 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lourdes Lago listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.